Dougherty & Co Affirms 'Buy' on Uroplasty (UPI); Allergan's (AGN) Entry Is Slight Positive...Near-Term

March 30, 2012 10:07 AM EDT
Get Alerts UPI Hot Sheet
Price: $1.22 --0%

Rating Summary:
    2 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Dougherty & Co affirms 'Buy' on Uroplasty (NASDAQ: UPI) price target lowered from $6.50 to $5.

Analyst, Deepak Chaulagai, said, "We think the potential entry of Allergan (NYSE: AGN) into the idiopathic market could bring further awareness to the OAB market – a slight positive for UPI. On the other hand, competition could slow UPI’s growth over the long-term. However, we think UPI has ample room to grow with a superior therapy to serve a large and underserved $3b+ OAB market. That is why we are affirming our Rating but lowering our price target (PT) to $5."

For an analyst ratings summary and ratings history on Uroplasty click here. For more ratings news on Uroplasty click here.

Shares of Uroplasty closed at $3.14 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change